 Our study found that COVID-19 patients treated with pre-exposure prophylaxis, PrEP, with tixajivimab-slash-silgavimab, T-slash-C, had a significantly lower risk of requiring hospitalization than those without PrEP. This suggests that T-slash-C may provide protection from severe COVID-19 infection. However, given the presence of multiple therapies and changing virus variants, further studies are needed to fully understand the efficacy of T-slash-C in the current Omicron era.